Seminars in Oncology
Volume 35, Issue 1 , Pages 11-16 , February 2008

The Epidemiology of Inflammatory Breast Cancer

  • Paul H. Levine

      Affiliations

    • Corresponding Author InformationAddress correspondence to Paul H. Levine, MD, Department of Epidemiology and Biostatistics, The George Washington University School of Public Health and Health Services, Ross Hall 118, 2300 I St NW, Washington, DC 20037.
    • ,
  • Carmela Veneroso

References 

  1. Hance KW, Anderson WF, Devesa SS, Young HA, Levine PH. Trends in inflammatory breast carcinoma incidence and survival: the Surveillance, Epidemiology, and End Results program at the National Cancer Institute. J Natl Cancer Inst. 2005;97:966–975
  2. Tabbane F, Muenz L, Jaziri M, Cammoun M, Belhassen S, Mourali N. Clinical and prognostic features of a rapidly progressing breast cancer in Tunisia. Cancer. 1977;40:376–382
  3. Greene FL, Page DL, Fritz A, Balch CM, Haller DG, Morrow M. Breast. In: AJCC cancer staging manual. New York: Springer-Verlag; 2002;p. 255–281
  4. Kim T, Lau J, Erban J. Lack of uniform diagnostic criteria for inflammatory breast cancer limits interpretation of treatment outcomes: a systematic review. Clin Breast Cancer. 2006;7:386–395
  5. Anderson WF, Schairer C, Chen BE, Hance KW, Levine PH. Epidemiology of inflammatory breast cancer (IBC). Breast Dis. 2005-6;22:9–23
  6. Bell C. In: A system of operative surgery. Vol. 2:Hartford, CT: Hale & Homser; 1814;p. 136
  7. Lee B, Tannenbaum N. Inflammatory carcinoma of the breast: a report of twenty-eight cases from the breast clinic of Memorial Hospital. Surg Gynecol Obstet. 1924;39:580–595
  8. Bryant T. Disease of the breast. Wood Medical and Surgical Mongraphs IV. 1889;
  9. Taylor G, Meltzer A. “Inflammatory carcinoma” of the breast. Am J Cancer. 1938;33:33–49
  10. Saltzstein SL. Clinically occult inflammatory carcinoma of the breast. Cancer. 1974;34:382–388
  11. Lucas FV, Perez-Mesa C. Inflammatory carcinoma of the breast. Cancer. 1978;41:1595–1605
  12. Amparo RS, Angel CD, Ana LH, Antonio LC, Vicente MS, Carlos FM, et al. Inflammatory breast carcinoma: pathological or clinical entity?. Breast Cancer Res Treat. 2000;64:269–273
  13. Levine PH, Steinhorn SC, Ries LG, Aron JL. Inflammatory breast cancer: the experience of the Surveillance, Epidemiology, and End Results (SEER) program. J Natl Cancer Inst. 1985;74:291–297
  14. Chang S, Parker SL, Pham T, Buzdar AU, Hursting SD. Inflammatory breast carcinoma incidence and survival: the Surveillance, Epidemiology, and End Results program of the National Cancer Institute, 1975-1992. Cancer. 1998;82:2366–2372
  15. Wingo PA, Jamison PM, Young JL, Gargiullo P. Population-based statistics for women diagnosed with inflammatory breast cancer (United States). Cancer Causes Control. 2004;15:321–328
  16. Mourali N, Tabbane F, Muenz LR, Behi J, Ben Moussa F, Jaziri M, et al. Ten-year results utilizing chemotherapy as primary treatment in nonmetastatic, rapidly progressing breast cancer. Cancer Invest. 1993;11:363–370
  17. Levine PH, Cartin BJ, Low JA, et al. Improving the case definition of inflammatory breast cancer. Breast Cancer Res Treat. 2005;94(Suppl 1):S89
  18. Portera CC, Yang SX, Wedam SB, et al. Evaluation of E-cadherin expression and lymphatic involvement in inflammatory breast cancer. Breast Cancer Res Treat. 2006;96(Suppl 1):S177
  19. Denoix P. Treatment of malignant breast cancer. Recent Results Cancer Res. 1970;31:92–94
  20. Mourali N, Muenz LR, Tabbane F, Belhassen S, Bahi J, Levine PH. Epidemiologic features of rapidly progressing breast cancer in Tunisia. Cancer. 1980;46:2741–2746
  21. Attia-Sobol I, Ferrier LP, Cure H, et al. Treatment results, survival and prognostic factors in 109 inflammatory breast cancer patients: univariate and multivariate analysis. Eur J Cancer. 1993;29A:1081–1088
  22. Bonnier P, Charpin C, Lejeune C, Romain S, Tubiana N, Beedassy B, et al. Inflammatory carcinomas of the breast: a clinical, pathological, or a clinical and pathological definition?. Int J Cancer. 1995;62:382–385
  23. Maalej M, Frikha H, Ben Salem S, Daoud J, Bouaouina N, Ben Abdallah M, et al. Breast cancer in Tunisia: clinical and epidemiological study. Bull Cancer. 1999;86:302–306
  24. Anderson WF, Chu KC, Chang S. Inflammatory breast carcinoma and noninflammatory locally advanced breast carcinoma: distinct clinicopathologic entities?. J Clin Oncol. 2003;21:2254–2259
  25. American Cancer Society. Cancer Facts and Figures. 2007;http://www.cancer.org/STT/CAFF2007PWSecured.pdf
  26. Chang S, Buzdar AU, Hursting SD. Inflammatory breast cancer and body mass index. J Clin Oncol. 1998;16:3731–3735
  27. Levine PH. Factors for the development of aggressive inflammatory and non-inflammatory breast cancer. Breast Cancer Res Treat. 2004;88(Suppl 1):S91
  28. Swanson CA, Brinton LA, Taylor PR, et al. Body size and breast cancer risk assessed in women participating in the Breast Cancer Detection Demonstration Project. Am J Epidemiol. 1989;130:1133–1141
  29. Le MG, Arriagada R, Bahi J, et al. Are risk factors for breast similar in women with inflammatory breast cancer and in those with non-inflammatory breast cancer?. Breast. 2006;15:355–362
  30. Levine PH, Mesa-Tejada R, Keydar I, et al. Increased incidence of mouse mammary tumor virus-related antigen in Tunisian patients with breast cancer. Int J Cancer. 1984;33:305–308
  31. Levine PH, Pogo BG, Coronel S, Woodson K, Klouj A, Melana SM, et al. Increasing evidence for a human breast cancer virus with geographic differences. Cancer. 2004;101:721–726
  32. Shiramizu B, Barriga F, Neequaye J, et al. Patterns of chromosomal breakpoint locations in Burkitt’s lymphoma: relevance to geography and Epstein-Barr virus association. Blood. 1991;77:1516–1526
  33. Levine PH, Kamaraju LS, Connelly RR, et al. The American Burkitt’s lymphoma registry: eight years’ experience. Cancer. 1982;49:1016–1022

PII: S0093-7754(07)00243-6

doi: 10.1053/j.seminoncol.2007.11.018

Seminars in Oncology
Volume 35, Issue 1 , Pages 11-16 , February 2008

Article Tools